{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:30:35Z","timestamp":1794324635837,"version":"4.9.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008444","name":"Parkinsonfonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008444","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Karin and Sten M\u00f6rtstedt CBD Solutions AB"},{"name":"ALF program of the Stockholm"},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100020410","name":"John and Lucille Van Geest Foundation","doi-asserted-by":"publisher","award":["2018"],"award-info":[{"award-number":["2018"]}],"id":[{"id":"10.13039\/501100020410","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nordstjernan","award":["2021"],"award-info":[{"award-number":["2021"]}],"id":[{"id":"https:\/\/ror.org\/021mtev94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Lexa International","award":["2021"],"award-info":[{"award-number":["2021"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a need for biomarkers to support an accurate diagnosis of Parkinson\u2019s disease (PD). Cerebrospinal fluid (CSF) has been a successful biofluid for finding neurodegenerative biomarkers, and modern highly sensitive multiplexing methods offer the possibility to perform discovery studies. Using a large-scale multiplex proximity extension assay (PEA) approach, we aimed to discover novel diagnostic protein biomarkers allowing accurate discrimination of PD from both controls and atypical Parkinsonian disorders (APD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CSF from patients with PD, corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), multiple system atrophy and controls, were analysed with Olink PEA panels. Three cohorts were used in this study, comprising 192, 88 and 36 cases, respectively. All samples were run on the Cardiovascular II, Oncology II and Metabolism PEA panels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our analysis revealed that 26 and 39 proteins were differentially expressed in the CSF of test and validation PD cohorts, respectively, compared to controls. Among them, 6 proteins were changed in both cohorts. Midkine (MK) was increased in PD with the strongest effect size and results were validated with ELISA. Another most increased protein in PD, DOPA decarboxylase (DDC), which catalyses the decarboxylation of DOPA (\n                      <jats:italic>L<\/jats:italic>\n                      -3,4-dihydroxyphenylalanine) to dopamine, was strongly correlated with dopaminergic treatment. Moreover, Kallikrein 10 was specifically changed in APD compared with both PD and controls, but unchanged between PD and controls. Wnt inhibitory factor 1 was consistently downregulated in CBS and PSP patients in two independent cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using the large-scale PEA approach, we have identified potential novel PD diagnostic biomarkers, most notably MK and DDC, in the CSF of PD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40035-023-00374-w","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:02:33Z","timestamp":1693810953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease"],"prefix":"10.1186","volume":"12","author":[{"given":"Wojciech","family":"Paslawski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Khosousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Markaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-3802","authenticated-orcid":false,"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"1","key":"374_CR1","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/s41598-020-59414-4","volume":"10","author":"MS Rotunno","year":"2020","unstructured":"Rotunno MS, Lane M, Zhang W, Wolf P, Oliva P, Viel C, et al. Cerebrospinal fluid proteomics implicates the granin family in Parkinson\u2019s disease. Sci Rep. 2020;10(1):2479.","journal-title":"Sci Rep"},{"issue":"6","key":"374_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/mds.26635","volume":"31","author":"S Halbgebauer","year":"2016","unstructured":"Halbgebauer S, Ockl P, Wirth K, Steinacker P, Otto M. Protein biomarkers in Parkinson\u2019s disease: focus on cerebrospinal fluid markers and synaptic proteins. Mov Disord. 2016;31(6):848\u201360.","journal-title":"Mov Disord"},{"issue":"10","key":"374_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812\u20138.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"374_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orru CD, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140(1):49\u201362.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"374_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407\u201317.","journal-title":"Lancet Neurol"},{"issue":"5","key":"374_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 2021;20(5):385\u201397.","journal-title":"Lancet Neurol"},{"issue":"10","key":"374_CR7","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/jnnp-2013-307539","volume":"85","author":"N Magdalinou","year":"2014","unstructured":"Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry. 2014;85(10):1065\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"374_CR8","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"374_CR9","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.","journal-title":"Nat Commun"},{"issue":"8","key":"374_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623\u201336.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"374_CR11","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192.","journal-title":"PLoS ONE"},{"issue":"1","key":"374_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun. 2019;7(1):169.","journal-title":"Acta Neuropathol Commun"},{"issue":"23","key":"374_CR13","doi-asserted-by":"publisher","first-page":"12952","DOI":"10.1073\/pnas.1912839117","volume":"117","author":"J Huang","year":"2020","unstructured":"Huang J, Khademi M, Fugger L, Lindhe O, Novakova L, Axelsson M, et al. Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117(23):12952\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"374_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/proteomes6030032","volume":"6","author":"BC Carlyle","year":"2018","unstructured":"Carlyle BC, Trombetta BA, Arnold SE. Proteomic approaches for the discovery of biofluid biomarkers of neurodegenerative dementias. Proteomes. 2018;6(3):32.","journal-title":"Proteomes"},{"issue":"7","key":"374_CR15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/jnnp-2018-320151","volume":"90","author":"E Jabbari","year":"2019","unstructured":"Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D, et al. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2019;90(7):768\u201373.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"374_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12883-020-1608-8","volume":"20","author":"A Santaella","year":"2020","unstructured":"Santaella A, Kuiperij HB, van Rumund A, Esselink RAJ, van Gool AJ, Bloem BR, et al. Inflammation biomarker discovery in Parkinson\u2019s disease and atypical parkinsonisms. BMC Neurol. 2020;20(1):26.","journal-title":"BMC Neurol"},{"issue":"12","key":"374_CR17","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"1","key":"374_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0022-510X(98)00304-9","volume":"163","author":"S Gilman","year":"1999","unstructured":"Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94\u20138.","journal-title":"J Neurol Sci"},{"issue":"6","key":"374_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364.","journal-title":"Mov Disord"},{"issue":"5","key":"374_CR20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503.","journal-title":"Neurology"},{"issue":"6","key":"374_CR21","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/mds.28545","volume":"36","author":"I Markaki","year":"2021","unstructured":"Markaki I, Ntetsika T, Sorjonen K, Svenningsson P, BioPark Study Group. Euglycemia indicates favorable motor outcome in Parkinson\u2019s disease. Mov Disord. 2021;36(6):1430\u20134.","journal-title":"Mov Disord"},{"issue":"15","key":"374_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord"},{"issue":"4","key":"374_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"15","key":"374_CR24","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25(15):2649\u201353.","journal-title":"Mov Disord"},{"issue":"5","key":"374_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing. 1997;26(5):353\u20137.","journal-title":"Age Ageing"},{"issue":"6","key":"374_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"374_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21(7):916\u201323.","journal-title":"Mov Disord"},{"issue":"2","key":"374_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193\u2013213.","journal-title":"Psychiatry Res"},{"issue":"6","key":"374_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/mds.26613","volume":"31","author":"UJ Kang","year":"2016","unstructured":"Kang UJ, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, et al. The BioFIND study: characteristics of a clinically typical Parkinson\u2019s disease biomarker cohort. Mov Disord. 2016;31(6):924\u201332.","journal-title":"Mov Disord"},{"issue":"30","key":"374_CR30","doi-asserted-by":"publisher","first-page":"15226","DOI":"10.1073\/pnas.1821409116","volume":"116","author":"W Paslawski","year":"2019","unstructured":"Paslawski W, Zareba-Paslawska J, Zhang X, Holzl K, Wadensten H, Shariatgorji M, et al. alpha-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson\u2019s disease patients. Proc Natl Acad Sci U S A. 2019;116(30):15226\u201335.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"374_CR31","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/mds.28543","volume":"36","author":"W Paslawski","year":"2021","unstructured":"Paslawski W, Bergstr\u00f6m S, Zhang X, Remnest\u00e5l J, He Y, Boxer A, et al. Cerebrospinal fluid proteins altered in corticobasal degeneration. Mov Disord. 2021;36(5):1278\u201380.","journal-title":"Mov Disord"},{"issue":"1","key":"374_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-020-00914-9","volume":"8","author":"H Geut","year":"2020","unstructured":"Geut H, Hepp DH, Foncke E, Berendse HW, Rozemuller JM, Huitinga I, et al. Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Acta Neuropathol Commun. 2020;8(1):39.","journal-title":"Acta Neuropathol Commun"},{"key":"374_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-015-0087-1","volume":"5","author":"SR Suwijn","year":"2015","unstructured":"Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson\u2019s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5:12.","journal-title":"EJNMMI Res"},{"issue":"2","key":"374_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ags3.12226","volume":"3","author":"M Ito","year":"2019","unstructured":"Ito M, Oshima Y, Yajima S, Suzuki T, Nanami T, Shiratori F, et al. Diagnostic impact of high serum midkine level in patients with gastric cancer. Ann Gastroenterol Surg. 2019;3(2):195\u2013201.","journal-title":"Ann Gastroenterol Surg"},{"issue":"7","key":"374_CR35","doi-asserted-by":"publisher","first-page":"e0180511","DOI":"10.1371\/journal.pone.0180511","volume":"12","author":"X Jing","year":"2017","unstructured":"Jing X, Cui X, Liang H, Hao C, Han C. Diagnostic accuracy of ELISA for detecting serum midkine in cancer patients. PLoS ONE. 2017;12(7):e0180511.","journal-title":"PLoS ONE"},{"issue":"12","key":"374_CR36","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1111\/bph.12601","volume":"171","author":"DR Jones","year":"2014","unstructured":"Jones DR. Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Br J Pharmacol. 2014;171(12):2925\u201339.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"374_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1054\/bjoc.2000.1339","volume":"83","author":"S Ikematsu","year":"2000","unstructured":"Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 2000;83(6):701\u20136.","journal-title":"Br J Cancer"},{"key":"374_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-94-007-4234-5_14","volume-title":"Midkine: from embryogenesis to pathogenesis and therapy","author":"E Shimizu","year":"2012","unstructured":"Shimizu E, Matsuzawa D. Midkine in psychiatric and neurodegenerative diseases. In: Erg\u00fcven M, Muramatsu T, Bilir A, editors. Midkine: from embryogenesis to pathogenesis and therapy. Dordrecht: Springer Netherlands; 2012. p. 165\u201370."},{"issue":"3","key":"374_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.pnpbp.2009.02.005","volume":"33","author":"S Ohgake","year":"2009","unstructured":"Ohgake S, Shimizu E, Hashimoto K, Okamura N, Koike K, Koizumi H, et al. Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):541\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"374_CR40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00702-010-0568-3","volume":"118","author":"RD Prediger","year":"2011","unstructured":"Prediger RD, Rojas-Mayorquin AE, Aguiar AS Jr, Chevarin C, Mongeau R, Hamon M, et al. Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson\u2019s disease. J Neural Transm (Vienna). 2011;118(8):1215\u201325.","journal-title":"J Neural Transm (Vienna)"},{"issue":"8","key":"374_CR41","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1159\/000508255","volume":"181","author":"X Liu","year":"2020","unstructured":"Liu X, Sun S, Liu D. IL-17D: a less studied cytokine of IL-17 family. Int Arch Allergy Immunol. 2020;181(8):618\u201323.","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"374_CR42","doi-asserted-by":"publisher","first-page":"16547","DOI":"10.1038\/s41598-017-16702-w","volume":"7","author":"G Casella","year":"2017","unstructured":"Casella G, Finardi A, Descamps H, Colombo F, Maiorino C, Ruffini F, et al. IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression. Sci Rep. 2017;7(1):16547.","journal-title":"Sci Rep"},{"key":"374_CR43","first-page":"229","volume":"5","author":"W Poewe","year":"2010","unstructured":"Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson\u2019s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229\u201338.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"374_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000215875","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62(1):1\u20138.","journal-title":"Eur Neurol"},{"key":"374_CR45","doi-asserted-by":"publisher","unstructured":"Rutledge J, Lehallier B, Zarifkar P, Losada PM, Ryman S, Yutsis M, et al. Aromatic L-Amino Acid Decarboxylase is a novel fluid biomarker of Parkinson\u2019s disease. Preprint at https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2022.11.09.22282149v1","DOI":"10.1101\/2022.11.09.22282149v1"},{"key":"374_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2013.12.020","volume":"546","author":"M Bertoldi","year":"2014","unstructured":"Bertoldi M. Mammalian Dopa decarboxylase: structure, catalytic activity and inhibition. Arch Biochem Biophys. 2014;546:1\u20137.","journal-title":"Arch Biochem Biophys"},{"issue":"9","key":"374_CR47","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/npp.2016.31","volume":"41","author":"DP Eisenberg","year":"2016","unstructured":"Eisenberg DP, Kohn PD, Hegarty CE, Ianni AM, Kolachana B, Gregory MD, et al. Common variation in the DOPA decarboxylase (DDC) gene and human striatal DDC activity in vivo. Neuropsychopharmacology. 2016;41(9):2303\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"374_CR48","doi-asserted-by":"publisher","first-page":"520934","DOI":"10.3389\/fneur.2020.520934","volume":"11","author":"L Li","year":"2020","unstructured":"Li L, Lin H, Hua P, Yan L, Dong H, Li T, et al. Polymorphism of the Dopa-decarboxylase gene modifies the motor response to levodopa in Chinese patients with Parkinson\u2019s disease. Front Neurol. 2020;11:520934.","journal-title":"Front Neurol"},{"issue":"2","key":"374_CR49","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.parkreldis.2013.10.017","volume":"20","author":"D Devos","year":"2014","unstructured":"Devos D, Lejeune S, Cormier-Dequaire F, Tahiri K, Charbonnier-Beaupel F, Rouaix N, et al. Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(2):170\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"374_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00702-020-02149-3","volume":"127","author":"H Mochizuki","year":"2020","unstructured":"Mochizuki H, Choong CJ, Baba K. Parkinson\u2019s disease and iron. J Neural Transm (Vienna). 2020;127(2):181\u20137.","journal-title":"J Neural Transm (Vienna)"},{"key":"374_CR51","volume-title":"Trends in Cell Signaling Pathways in Neuronal Fate Decision","author":"U Ueberham","year":"2013","unstructured":"Ueberham U, Arendt T. The role of Smad proteins for development, differentiation and dedifferentiation of neurons. In: Wislet-Gendebien S, editor. Trends in Cell Signaling Pathways in Neuronal Fate Decision. UK: IntechOpen; 2013."},{"issue":"1","key":"374_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2008.302","volume":"19","author":"X Guo","year":"2009","unstructured":"Guo X, Wang XF. Signaling cross-talk between TGF-beta\/BMP and other pathways. Cell Res. 2009;19(1):71\u201388.","journal-title":"Cell Res"},{"issue":"7","key":"374_CR53","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1172\/JCI31342","volume":"117","author":"JL Babitt","year":"2007","unstructured":"Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933\u20139.","journal-title":"J Clin Invest"},{"issue":"37","key":"374_CR54","doi-asserted-by":"publisher","first-page":"12252","DOI":"10.1523\/JNEUROSCI.1305-10.2010","volume":"30","author":"L Crews","year":"2010","unstructured":"Crews L, Adame A, Patrick C, Delaney A, Pham E, Rockenstein E, et al. Increased BMP6 levels in the brains of Alzheimer\u2019s disease patients and APP transgenic mice are accompanied by impaired neurogenesis. J Neurosci. 2010;30(37):12252\u201362.","journal-title":"J Neurosci"},{"issue":"8","key":"374_CR55","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/j.1460-9568.1997.tb01527.x","volume":"9","author":"J Jordan","year":"1997","unstructured":"Jordan J, Bottner M, Schluesener HJ, Unsicker K, Krieglstein K. Bone morphogenetic proteins: neurotrophic roles for midbrain dopaminergic neurons and implications of astroglial cells. Eur J Neurosci. 1997;9(8):1699\u2013709.","journal-title":"Eur J Neurosci"},{"issue":"9","key":"374_CR56","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1172\/JCI10403","volume":"107","author":"MP Herman","year":"2001","unstructured":"Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001;107(9):1117\u201326.","journal-title":"J Clin Invest"},{"issue":"12","key":"374_CR57","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/ATVBAHA.109.198929","volume":"29","author":"N Mackman","year":"2009","unstructured":"Mackman N, Taubman M. Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol. 2009;29(12):1986\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"19","key":"374_CR58","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","volume":"123","author":"JP Wood","year":"2014","unstructured":"Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934\u201343.","journal-title":"Blood"},{"issue":"11","key":"374_CR59","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1161\/STROKEAHA.113.000736","volume":"44","author":"MJ Fisher","year":"2013","unstructured":"Fisher MJ. Brain regulation of thrombosis and hemostasis: from theory to practice. Stroke. 2013;44(11):3275\u201385.","journal-title":"Stroke"},{"key":"374_CR60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.biochi.2015.09.002","volume":"122","author":"T Kryza","year":"2016","unstructured":"Kryza T, Silva ML, Loessner D, Heuze-Vourc\u2019h N, Clements JA. The kallikrein-related peptidase family: dysregulation and functions during cancer progression. Biochimie. 2016;122:283\u201399.","journal-title":"Biochimie"},{"key":"374_CR61","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.biochi.2015.09.023","volume":"122","author":"M Kalinska","year":"2016","unstructured":"Kalinska M, Meyer-Hoffert U, Kantyka T, Potempa J. Kallikreins\u2014the melting pot of activity and function. Biochimie. 2016;122:270\u201382.","journal-title":"Biochimie"},{"issue":"166","key":"374_CR62","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fncel.2020.00166","volume":"14","author":"C Mella","year":"2020","unstructured":"Mella C, Figueroa CD, Otth C, Ehrenfeld P. Involvement of kallikrein-related peptidases in nervous system disorders. Front Cell Neurosci. 2020;14(166):166.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"374_CR63","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.clinbiochem.2003.11.012","volume":"37","author":"EP Diamandis","year":"2004","unstructured":"Diamandis EP, Scorilas A, Kishi T, Blennow K, Luo LY, Soosaipillai A, et al. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer\u2019s disease and frontotemporal dementia. Clin Biochem. 2004;37(3):230\u20137.","journal-title":"Clin Biochem"},{"issue":"1","key":"374_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11\u201326.","journal-title":"Nat Rev Cancer"},{"key":"374_CR65","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fcell.2018.00167","volume":"6","author":"L Poggi","year":"2018","unstructured":"Poggi L, Casarosa S, Carl M. An eye on the Wnt inhibitory factor Wif1. Front Cell Dev Biol. 2018;6:167.","journal-title":"Front Cell Dev Biol"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-023-00374-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T07:45:21Z","timestamp":1700379921000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-023-00374-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1186\/s40035-023-00374-w","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study individuals gave written consent to the storage of their samples for future use in studies; and the study has been approved by the Swedish Ethical Review Authority (dnr 2020-03684). The PD patients included were additionally part of the Stockholm BioPark cohort (dnr 2019-04967) and had been clinically assessed. The PD validation cohort used in the study originated from BioFIND (\n                      \n                      ). The institutional review board of BioFIND approved the study protocol. Written informed consent was obtained from each study participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no competing interests. WP reports grants unrelated to this work from \u00c5ke Wibergs Stiftelse and The Michael J. Fox Foundation for Parkinson\u2019s Research. AB reports consultancy unrelated to this work for AGTC, Alector (stock\/options), Arkuda (options), Arvinas (options), Asceneuron, AZTherapies (options), Bioage, GSK, Humana, Lundbeck, Ono, Roche, Samumed, Sangamo, Stealth Therapeutics, Third Rock, Transposon, UCB and Wave, and received research support from the Association for Frontotemporal Degeneration, Biogen, Bluefield Project to Cure Frontotemporal Dementia, Eli Lilly, Eisai, National Institutes of Health (U19AG063911, U54NS092089, R01AG031278), and the Rainwater Charitable Foundation. PS reports grants from Karin and Sten M\u00f6rtstedt CBD Solutions AB, the Swedish Parkinson fund, the ALF program of the Stockholm Stockholm City, Knut and Alice Wallenberg Foundation, The Michael J. Fox Foundation for Parkinson\u2019s Research, the Swedish Parkinson foundation, Lexa\/Nordstjernan, ASAP, and Van Geest Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}